Evidence map›Paper›PMID 34313406›Full record

ArticleACR open rheumatology2021

Kawasaki Disease: A Systematic Review and Meta-Analysis of Benefits and Harms of Common Treatments.

Karen E James, Mohamad A Kalot, Nedaa M Husainat, Anisha B Dua, Kevin Byram, Jason M Springer, Yih Chang Lin, Marat Turgunbaev, Alexandra Villa-Forte, Mark Gorelik and 5 more

Open access · goldAbstract read
In one paragraph

Article in ACR open rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. An Update on Kawasaki Disease.Current rheumatology reports · 2024
    Review
  5. Multiresistant Kawasaki Disease in a Young Infant with Giant Aneurysms Growing Fast.Journal of cardiovascular development and disease · 2024
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 1 country.

Karen E JamesUniversity of Utah Health, Salt Lake City, Utah.
Mohamad A KalotState University of New York at Buffalo, Buffalo, New York.ORCID https://orcid.org/0000-0002-6581-4561
Nedaa M HusainatSt. Mary's Hospital, Saint Louis, Missouri.ORCID https://orcid.org/0000-0002-9638-2992
Anisha B DuaNorthwestern University Feinberg School of Medicine, Chicago, Illinois.
Kevin ByramVanderbilt University Medical Center, Nashville, Tennessee.
Jason M SpringerVanderbilt University Medical Center, Nashville, Tennessee.ORCID https://orcid.org/0000-0002-3903-6049
Yih Chang LinUniversity of South Florida, Tampa, Florida.
Marat TurgunbaevClinical Practice Guidelines, American College of Rheumatology, Atlanta, Georgia.
Alexandra Villa-ForteCleveland Clinic, Cleveland, Ohio.
Mark GorelikMayo Clinic, Jacksonville, Florida.
Andy AbrilColumbia University Irving Medical Center, New York, New York.
Carol LangfordCleveland Clinic, Cleveland, Ohio.
Mehrdad MazUniversity of Kansas Medical Center, Kansas City, KS.
Sharon A ChungUniversity of California, San Francisco Medical Center.
Reem A MustafaUniversity of Kansas Medical Center, Kansas City, KS.ORCID https://orcid.org/0000-0002-2091-0875
Cleveland Clinic · USUniversity of Kansas Medical Center · USVanderbilt University Medical Center · USAmerican College of Rheumatology · USColumbia University Irving Medical Center · USJacksonville College · USNorthwestern University · USSt. Mary's Hospital · USUniversity at Buffalo, State University of New York · USUniversity of California San Francisco Medical Center · USUniversity of South Florida · USUniversity of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveKawasaki disease (KD) is a self-limited vasculitis affecting medium-sized vessels with a predilection for the coronary arteries. Although treatment reduces the likelihood of developing of coronary artery aneurysms, 5% of patients still develop aneurysms despite treatment, making KD the leading cause of acquired heart disease in children in the United States. Consequently, there is a great deal of interest in optimizing treatment regimens, particularly for higher-risk patients, to decrease morbidity. The aim of this systematic review is to support the development of the American College of Rheumatology/Vasculitis Foundation for the diagnosis and management of KD, focusing on the more complex scenarios in which rheumatologists may become involved, such as high-risk and refractory disease.

methodsEighty-nine articles were considered for full review in this systematic literature review to address 16 Population, Intervention, Comparison, and Outcome questions related to KD. Data were abstracted in hierarchical fashion. Randomized control trials (RCTs) were considered first; if none were identified or if they contained insufficient information, comparative observational studies were then viewed, followed by single-arm observational studies/single arms from comparative studies. Only observational studies with more than 10 subjects with vasculitis were included.

resultsEight RCTs and 28 observational studies that addressed the questions were identified. Two questions were addressed by RCTs, seven questions had at least some comparative observational studies, three questions were only addressed by single-arm data, and four questions had no relevant studies.

conclusionThis systematic review evaluates the benefits and harms of treatments for KD beyond first-line therapy.

Identifiers

PMID34313406
PMCPMC8516108
OpenAlexW3184652980

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.